Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound)
In the 1990s, exendin-4, a GLP-1 receptor agonist (GLP-1 RA) structurally similar to endogenous GLP-1, was isolated from Gila monster venom, which subsequently led to the approval of exenatide for type 2 diabetes mellitus (T2DM) management in 2005 [2]
Limited research exists
When changing any transdermal patch, patients should remove the old patch carefully, fold it in half with the adhesive sides together, and dispose of it safely according to the medication guidetypically in a sealed container out of reach of children and pets
Meena Malhotra, an Illinois-based internist specializing in obesity
Discontinuation of treatment or switching between agents should be reserved for patients with persistent or severe symptoms despite optimised management strategies